Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D, Polerà N, Belmonte B, Conforti F, Signorelli S, Gulino A, Staropoli N, Tuccillo FM, Bonelli P, Juli G, Grillone K, Ascrizzi S, Cirillo M, Migale L, Ballerini A, Pelizon C, Di Martino MT, Tagliaferri P, Riillo C, Tassone P. Caracciolo D, et al. Among authors: polera n. Br J Haematol. 2024 Feb;204(2):555-560. doi: 10.1111/bjh.19183. Epub 2023 Nov 14. Br J Haematol. 2024. PMID: 37963444
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C, Polerà N, Di Martino MT, Juli G, Hokanson CA, Odineca T, Signorelli S, Grillone K, Ascrizzi S, Mancuso A, Staropoli N, Caparello B, Cerra M, Nisticò G, Tagliaferri P, Crea R, Caracciolo D, Tassone P. Riillo C, et al. Among authors: polera n. J Transl Med. 2023 May 4;21(1):301. doi: 10.1186/s12967-023-04101-x. J Transl Med. 2023. PMID: 37143061 Free PMC article.
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.
Polerà N, Mancuso A, Riillo C, Caracciolo D, Signorelli S, Grillone K, Ascrizzi S, Hokanson CA, Conforti F, Staropoli N, Gervasi L, Di Martino MT, Arbitrio M, Nisticò G, Crea R, Tagliaferri P, Juli G, Tassone P. Polerà N, et al. Cancers (Basel). 2023 Mar 8;15(6):1647. doi: 10.3390/cancers15061647. Cancers (Basel). 2023. PMID: 36980534 Free PMC article.
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.
Scionti F, Juli G, Rocca R, Polerà N, Nadai M, Grillone K, Caracciolo D, Riillo C, Altomare E, Ascrizzi S, Caparello B, Cerra M, Arbitrio M, Richter SN, Artese A, Alcaro S, Tagliaferri P, Tassone P, Di Martino MT. Scionti F, et al. Among authors: polera n. J Exp Clin Cancer Res. 2023 Mar 27;42(1):71. doi: 10.1186/s13046-023-02633-0. J Exp Clin Cancer Res. 2023. PMID: 36967378 Free PMC article.
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.
Caracciolo D, Juli G, Riillo C, Coricello A, Vasile F, Pollastri S, Rocca R, Scionti F, Polerà N, Grillone K, Arbitrio M, Staropoli N, Caparello B, Britti D, Loprete G, Costa G, Di Martino MT, Alcaro S, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: polera n. J Transl Med. 2022 Oct 22;20(1):482. doi: 10.1186/s12967-022-03705-z. J Transl Med. 2022. PMID: 36273153 Free PMC article.
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma.
Grillone K, Riillo C, Rocca R, Ascrizzi S, Spanò V, Scionti F, Polerà N, Maruca A, Barreca M, Juli G, Arbitrio M, Di Martino MT, Caracciolo D, Tagliaferri P, Alcaro S, Montalbano A, Barraja P, Tassone P. Grillone K, et al. Among authors: polera n. Int J Mol Sci. 2022 Sep 6;23(18):10222. doi: 10.3390/ijms231810222. Int J Mol Sci. 2022. PMID: 36142133 Free PMC article.
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Riillo C, Caracciolo D, Grillone K, Polerà N, Tuccillo FM, Bonelli P, Juli G, Ascrizzi S, Scionti F, Arbitrio M, Lopreiato M, Siciliano MA, Sestito S, Talarico G, Galea E, Galati MC, Pensabene L, Loprete G, Rossi M, Ballerini A, Gentile M, Britti D, Di Martino MT, Tagliaferri P, Tassone P. Riillo C, et al. Among authors: polera n. Cancers (Basel). 2022 Jun 11;14(12):2886. doi: 10.3390/cancers14122886. Cancers (Basel). 2022. PMID: 35740552 Free PMC article.
miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma.
Caracciolo D, Riillo C, Juli G, Scionti F, Todoerti K, Polerà N, Grillone K, Fiorillo L, Arbitrio M, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: polera n. Cancers (Basel). 2021 Aug 29;13(17):4365. doi: 10.3390/cancers13174365. Cancers (Basel). 2021. PMID: 34503175 Free PMC article.
16 results